Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03792841
Title Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Amgen

prostate cancer


AMG 160 + Pembrolizumab

AMG 160

Age Groups: senior | adult
Covered Countries USA | FRA | CAN | BEL | AUT

No variant requirements are available.